Join Growin Stock Community!

Soligenix, inc.SNGX.US Overview

US StockHealthcare
(No presentation for SNGX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SNGX AI Insights

SNGX Overall Performance

SNGX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SNGX Recent Performance

-5.13%

Soligenix, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

SNGX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SNGX Key Information

SNGX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SNGX Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Price of SNGX

SNGX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SNGX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.14
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3874.85
PB Ratio
1.53
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
0.00%
Net Margin
-409394.19%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.14
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3874.85
PB Ratio
1.53
Price-to-FCF
-
Gross Margin
0.00%
Net Margin
-409394.19%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is SNGX's latest earnings report released?

    The most recent financial report for Soligenix, inc. (SNGX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SNGX's short-term business performance and financial health. For the latest updates on SNGX's earnings releases, visit this page regularly.

  • How much debt does SNGX have?

    As of the end of the reporting period, Soligenix, inc. (SNGX) had total debt of 385.05K, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SNGX have?

    At the end of the period, Soligenix, inc. (SNGX) held Total Cash and Cash Equivalents of 10.53M, accounting for 0.93 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SNGX's EPS continuing to grow?

    According to the past four quarterly reports, Soligenix, inc. (SNGX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.58. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SNGX?

    Soligenix, inc. (SNGX)'s Free Cash Flow (FCF) for the period is -2.93M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 0.78% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.